Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Mild Alzheimer's Disease

Start: February 2012
End: October 2013
Enrollment: 100

What Is This Study About?

This Phase I clinical trial will evaluate the safety and pharmacodynamic effects of the experimental drug BMS-241027 in people with mild Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 90 Years

Must have:

  • Mild Alzheimer's disease
  • Mini-Mental State Examination score of 20-26 inclusive
  • Cerebrospinal fluid laboratory results consistent with Alzheimer's pathology
  • Magnetic resonance brain imaging results showing atrophy consistent with Alzheimer's diagnosis; no more than mild white matter disease; up to two lacunar infarcts acceptable except in anterior thalamus, genu of internal capsule, or basal forebrain; no cortical infarcts; no more than four microbleeds; no focal asymmetric lobar atrophy or other findings suggesting primary cause of dementia other than Alzheimer's; no macrohemorrhages (>10 mm)
  • Reliable study partner
  • Non-childbearing potential

Must NOT have:

  • Medical condition other than mild Alzheimer's disease that could explain memory or cognitive deficits
  • History of stroke, gastrointestinal illness, or generalized peripheral neuropathy
  • Vitamin B12 or folate deficiency
  • Unstable cardiovascular, pulmonary, gastrointestinal, or hepatic disease within 30 days prior to screening
  • Active liver disease or history of hepatic intolerance
  • Geriatric Depression Scale score of ≥ 6 at screening
  • Diagnosis of or treatment for schizophrenia or bipolar disease within 3 years prior to screening

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Who Is the General Study Contact?

For information about U.S. sites, please call the telephone numbers in the chart below. For information about a site outside the United States, e-mail Clinical.Trials@bms.com. The first line of the e-mail must contain the clinical trials identifying number, NCT01492374, and the site number listed below. Only trial sites that are recruiting have contact information at this time.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Bristol-Myers Squibb

Source: ClinicalTrials.gov ID: NCT01492374

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health